Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 25 May 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted on 24 May to partially support Pfizer's drug, tafamadis, which is looking for FDA approval to treat a rare neurodegenerative disease.
The panel voted 13 to 4 against the drug in an initial vote, saying study data did not show the drug to be effective in directly slowing the progression of familial amyloid polyneuropathy (FAP). The committee later voted again, finding in a 13 to 4 decision that tafamadis was effective in treating surrogate endpoints associated with FAP such as limb function.
The split vote may spell trouble of tafamadis at FDA, reports Reuters, as its staff "recommended rejecting the drug saying the data did not prove that it worked well in treating the disease." Those concerns are likely to be weighed against the needs of the approximately 2,500 US patients suffering from FAP who currently lack medicinal options to treat the disorder, reports Med Page Today.
The drug is already approved by the European Medicines Agency (EMA) for the condition, and is marketed under the trade name Vyndaqel.
Read more:
Reuters - U.S. panel split on Pfizer rare disease drug
Med Page Today - FDA Panel Sends Mixed Message on Pfizer Drug
PMLiVE - FDA panel supports Pfizer's tafamidis despite efficacy concerns
The Pink Sheet Daily - Pfizer's Vyndaqel Splits Advisory Committee; Now It Must Move FDA
Tags: CNSDAC, Vyndaqel, Tafamadis, FAP, Pfizer, CNS, AdComm, Latest News, advisory committee
Regulatory Focus newsletters
All the biggest regulatory news and happenings.